Skip to main content
. 2006 Sep 26;95(8):1013–1019. doi: 10.1038/sj.bjc.6603366

Figure 1.

Figure 1

(A) Photomicrographs of p-PDGFR-β expression and tumour hypoxia (EF5) in control and after treatment with Imatinib. (B) p-PDGFR-β expression in tumour after 4 consecutive days of treatment with Imatinib (50 mg kg−1) (mean±s.e.m.). (C) Tumour hypoxia after 4 days of treatment with Imatinib (50 mg kg−1) (mean±s.e.m.)